Table 2.

Clinical Studies of Drugs Targeting VISTA

Clinical Trial Number	Drug	Tumor Type	Phase	Setting	Design	Actual Status	Summary Results
NCT02671955	JNJ-61,610,588	NSCLC, SCLC, head and neck, pancreatic, colorectal, cervical cancer	I	Advanced disease, >1 line	Single-arm, open label	Recruitment stopped in 2017	Results awaited
NCT02812875	CA-170	Solid tumors and lymphoma	I	Advanced disease, >2 line	Single-arm, open label	Enrolment ongoing	- Acceptable safety up to 2400 mg daily dosage - 50% stable disease
CTRI/2017/12/011026	CA-170	NSCLC, HN/oral cavity, MSI-High or dMMR cancers, HL	II	Advanced disease, previously treated with 1–3 lines	Randomized, multiple-arm, open label (comparison between 400 mg vs 800 mg)	Enrolment ongoing (estimated 130 patients)	- 59.5% of CBR - Trend towards higher activity with lower dosage

Abbreviations: NSCLC, non-small-cell lung cancer; SCLC, small-cell-lung cancer; HN, head and neck; MSI, microsatellite instability; dMMR, mismatch repair deficient; HL, Hodgkin lymphoma; CBR, clinical benefit rate.